JP2021098733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021098733A5 JP2021098733A5 JP2021037490A JP2021037490A JP2021098733A5 JP 2021098733 A5 JP2021098733 A5 JP 2021098733A5 JP 2021037490 A JP2021037490 A JP 2021037490A JP 2021037490 A JP2021037490 A JP 2021037490A JP 2021098733 A5 JP2021098733 A5 JP 2021098733A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555110P | 2017-09-07 | 2017-09-07 | |
| US62/555,110 | 2017-09-07 | ||
| US201762566824P | 2017-10-02 | 2017-10-02 | |
| US62/566,824 | 2017-10-02 | ||
| JP2020513796A JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513796A Division JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021098733A JP2021098733A (ja) | 2021-07-01 |
| JP2021098733A5 true JP2021098733A5 (https=) | 2021-10-14 |
Family
ID=65634405
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513796A Active JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
| JP2021037490A Pending JP2021098733A (ja) | 2017-09-07 | 2021-03-09 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
| JP2023132099A Pending JP2023166409A (ja) | 2017-09-07 | 2023-08-14 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
| JP2025026082A Pending JP2025093943A (ja) | 2017-09-07 | 2025-02-20 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513796A Active JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132099A Pending JP2023166409A (ja) | 2017-09-07 | 2023-08-14 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
| JP2025026082A Pending JP2025093943A (ja) | 2017-09-07 | 2025-02-20 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200277383A1 (https=) |
| EP (2) | EP3925976A1 (https=) |
| JP (4) | JP7431392B2 (https=) |
| KR (3) | KR20240167101A (https=) |
| CN (3) | CN111315782A (https=) |
| AU (3) | AU2018329937B2 (https=) |
| BR (1) | BR112020004489A2 (https=) |
| CA (2) | CA3074840A1 (https=) |
| IL (2) | IL273067A (https=) |
| MX (2) | MX420258B (https=) |
| RU (1) | RU2021110369A (https=) |
| SG (2) | SG11202001930QA (https=) |
| WO (1) | WO2019051308A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10696722B2 (en) | 2016-08-10 | 2020-06-30 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| SG11202104136YA (en) | 2018-10-23 | 2021-05-28 | Dragonfly Therapeutics Inc | Heterodimeric fc-fused proteins |
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| CN115427439A (zh) * | 2019-10-30 | 2022-12-02 | 德克萨斯A&M大学系统 | 用于双靶标嵌合抗原受体t细胞疗法的蛋白酶开关 |
| MX2022013112A (es) * | 2020-04-22 | 2023-01-16 | Dragonfly Therapeutics Inc | Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc. |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| KR20230091885A (ko) * | 2020-09-17 | 2023-06-23 | 어젠시스 인코포레이티드 | 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN113563474B (zh) * | 2021-06-11 | 2023-05-02 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | EpCAM-CD16-NKG2D三特异性抗体及其应用 |
| KR20240083868A (ko) * | 2021-08-20 | 2024-06-12 | 탈락 테라퓨틱스, 인크. | 넥틴-4 항체 및 접합체 |
| AR127162A1 (es) * | 2021-09-29 | 2023-12-27 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y baff-r |
| KR20230060546A (ko) * | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| EP4561624A1 (en) * | 2022-07-25 | 2025-06-04 | Agensys, Inc. | Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040038339A1 (en) * | 2000-03-24 | 2004-02-26 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| JP2003111595A (ja) * | 2001-06-25 | 2003-04-15 | Kyogo Ito | 腫瘍抗原 |
| CN1812999A (zh) * | 2003-05-31 | 2006-08-02 | 麦克罗梅特股份公司 | 包含EpCAM特异构建体的药物组合物 |
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| US8383118B2 (en) | 2005-12-08 | 2013-02-26 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
| US20110301056A1 (en) * | 2008-12-12 | 2011-12-08 | Oncotherapy Science, Inc. | Nectin-4 for target genes of cancer therapy and diagnosis |
| US8309093B2 (en) | 2009-03-06 | 2012-11-13 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins |
| GB0909904D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| WO2011003780A1 (en) * | 2009-07-06 | 2011-01-13 | F. Hoffmann-La Roche Ag | Bi-specific digoxigenin binding antibodies |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| MX347954B (es) * | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| US9562110B2 (en) * | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| US10047163B2 (en) * | 2013-02-08 | 2018-08-14 | Abbvie Stemcentrx Llc | Multispecific constructs |
| BR112016000853A2 (pt) * | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| EP3083696B1 (en) * | 2013-12-20 | 2018-02-14 | F.Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| KR20160122127A (ko) * | 2013-12-23 | 2016-10-21 | 자임워크스 인코포레이티드 | C-말단의 경쇄 폴리펩타이드 연장부를 포함하는 항체 및 이의 컨쥬게이트 및 이들의 사용방법 |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| WO2016134371A2 (en) | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| EP3347048B1 (en) * | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| AU2018219887B2 (en) * | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| BR112020015994A2 (pt) * | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) * | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| EP4301774A4 (en) * | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US20230416402A1 (en) * | 2022-03-03 | 2023-12-28 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2 |
-
2018
- 2018-09-07 SG SG11202001930QA patent/SG11202001930QA/en unknown
- 2018-09-07 CA CA3074840A patent/CA3074840A1/en active Pending
- 2018-09-07 EP EP21164073.5A patent/EP3925976A1/en not_active Withdrawn
- 2018-09-07 SG SG10202102502VA patent/SG10202102502VA/en unknown
- 2018-09-07 KR KR1020247038586A patent/KR20240167101A/ko active Pending
- 2018-09-07 BR BR112020004489-0A patent/BR112020004489A2/pt unknown
- 2018-09-07 CN CN201880071464.8A patent/CN111315782A/zh active Pending
- 2018-09-07 AU AU2018329937A patent/AU2018329937B2/en active Active
- 2018-09-07 EP EP18853095.0A patent/EP3679071A4/en active Pending
- 2018-09-07 CN CN202411838715.4A patent/CN119735693A/zh active Pending
- 2018-09-07 KR KR1020207009780A patent/KR20200044957A/ko not_active Ceased
- 2018-09-07 JP JP2020513796A patent/JP7431392B2/ja active Active
- 2018-09-07 CA CA3112984A patent/CA3112984A1/en active Pending
- 2018-09-07 US US16/644,585 patent/US20200277383A1/en not_active Abandoned
- 2018-09-07 RU RU2021110369A patent/RU2021110369A/ru unknown
- 2018-09-07 CN CN202110251101.6A patent/CN113004417A/zh active Pending
- 2018-09-07 MX MX2020002626A patent/MX420258B/es unknown
- 2018-09-07 KR KR1020217007213A patent/KR20210030503A/ko not_active Ceased
- 2018-09-07 WO PCT/US2018/050073 patent/WO2019051308A1/en not_active Ceased
-
2020
- 2020-03-04 IL IL273067A patent/IL273067A/en unknown
- 2020-03-06 MX MX2021002970A patent/MX2021002970A/es unknown
-
2021
- 2021-03-02 US US17/190,155 patent/US20210292420A1/en not_active Abandoned
- 2021-03-08 IL IL281323A patent/IL281323A/en unknown
- 2021-03-09 JP JP2021037490A patent/JP2021098733A/ja active Pending
- 2021-03-09 AU AU2021201494A patent/AU2021201494A1/en not_active Abandoned
-
2023
- 2023-02-13 US US18/108,961 patent/US20230357409A1/en active Pending
- 2023-08-14 JP JP2023132099A patent/JP2023166409A/ja active Pending
-
2024
- 2024-12-11 AU AU2024278313A patent/AU2024278313A1/en active Pending
-
2025
- 2025-02-20 JP JP2025026082A patent/JP2025093943A/ja active Pending